GSK endometrial cancer treatment gets Europe authorisation

The FTSE 100 pharmaceutical giant said the authorisation was specifically for the treatment of adult patients suffering from mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer, who were considered candidates for systemic therapy.

By combining Jemperli with carboplatin-paclitaxel, it said healthcare professionals would gain a valuable tool in addressing the specific needs of this patient population.

The company also noted that the conditional approval that Jemperli previously received as a monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that had progressed on or following prior treatment with a platinum-containing regimen had now been converted to full approval.

“People living with this type of endometrial cancer typically experience disease progression and poor-long term outcomes with current standard of care,” said Hesham Abdullah, senior vice-president and global head of oncology research and development at GSK.

“With this approval, we can expand the number of patients who can potentially benefit from treatment with Jemperli in Europe, including patients who are earlier in their journey.

“We are proud of the recent approvals for Jemperli as we believe that it continues to transform the frontline endometrial cancer treatment landscape and shows promise as a foundational immuno-oncology therapy.”

At 0804 GMT, shares in GSK were up 0.03% at 1,433.4p.

Reporting by Josh White for Sharecast.com.